Cardiol Therapeutics (CRDL) Canaccord Genuity’s 45th Annual Growth Conference summary

Company overview and clinical programs

• Focus on anti-inflammatory therapies for heart diseases including pericarditis, myocarditis, and heart failure.

• MAVRIC, a pivotal Phase III trial for recurrent pericarditis, is enrolling in the US and expanding to Europe and Canada.

• ARCHER, a late-stage program in acute myocarditis, recently reported positive top-line data impacting MRI-based measures.

• Published promising data on a subcutaneous asset for diastolic heart failure in the Journal of the American College of Cardiology.

• Orphan drug designations secured for pericarditis and potentially for myocarditis; heart failure affects 6 million Americans.

Recurrent pericarditis program and trial design

• CardiolRx™ aims to replace corticosteroids in recurrent pericarditis, targeting patients discontinuing IL-1 inhibitors.

• Trial design leverages a homogeneous population with a high recurrence rate, enabling clear efficacy assessment.

• Scientific Advisory Board includes global leaders in pericarditis, guiding trial design and execution.

• Oral therapy offers accessibility and safety advantages over expensive biologics and steroids.

• Regulatory path mirrors established precedents, de-risking the MAVRIC trial.

Acute myocarditis and ARCHER trial insights

• ARCHER is one of the largest corporate-sponsored studies in acute myocarditis, addressing a life-threatening condition with no standard of care.

• Strong expert support for advancing the therapy in myocarditis and other inflammatory cardiac conditions.

• Significant reduction in left ventricular mass observed, indicating anti-inflammatory effects.

• First observed improvements in acute myocarditis, potentially preventing irreversible fibrosis.

• ARCHER data provides a read-through for safety and efficacy to the MAVRIC trial.